A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
NCT00218205
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
973-676-1000
- Patient must have histologically proven adenocarcinoma of the prostate gland.
- Patient must have evidence of progressive metastatic disease (e.g., bone, pelvic mass, lymph node, liver or lung metastases) within 6 weeks prior to participation in the study.
- Patients must not have an elevated PSA level as the only evidence of disease. While castrated, the patients should have rising PSA on two consecutive measurements at least 1 week apart. The confirmatory PSA must be obtained within 1 week prior to study registration and should be >10ng/ml.
- Patients with bone metastases only (i.e., lacking soft-tissue disease) must have a PSA level of > 10 ng/ml. Patients with soft tissue metastases and /or visceral disease must have either measurable disease or a PSA level of > 10 ng/ml.
- Radiological evidence of hydronephrosis will not by itself constitute evidence of metastatic disease.
- Patients must have had prior treatment with bilateral orchiectomy or other primary hormonal therapy (e.g., estrogen therapy, LHRH analog + flutamide, etc.) with evidence of treatment failure.
NOTE: Patients who have not undergone bilateral orchiectomy must continue LHRH agonist therapy (e.g., depot leuprolide or goserelin) while receiving this protocol therapy.
- For patients previously treated with flutamide (Eulexin), nilutamide (Nilandron), or bicalutamide (Casodex): Patients must have discontinued flutamide or nilutamide < 4 weeks and for bicalutamide 6 weeks prior to registration.
- Patients should not have prior exposure to anthracyclines or estramustine phosphate.
- Patients must not have had prior radiotherapy < 4 weeks prior to this protocol treatment.
- Patients must not have previously received Strontium 89, Samarium 153, or other radioisotope therapies.
- Patients must have recovered from all toxicities due to prior treatment for prostate cancer prior to receiving this protocol treatment.
- Patients must have adequate bone marrow function: (WBC > 4000/ mm3, granulocytes > 2000/ mm3, platelet count > 100,000/mm3, and Hemoglobin > 8.0 g/dl < 4 weeks prior to participate in this study.
- Patients must have the following chemistry values < 4 weeks prior to participate in this study:
- Bilirubin < 1.5 mg/dl
- Transaminases (SGOT and/or SGPT) < 5 x institutional upper limit of normal (ULN)
- Creatinine < 2.0 mg/d. or creatinine clearance > 50 ml/min
- Alkaline phosphatase £ 5 x ULN
- Patients must have no active angina pectoris, or known heart disease of New York Heart Association Class III-IV. Patients must not have a history of myocardial infarction < 6 months prior to the study participation.
- Patients with a history of prior malignancy are eligible provided they were treated with curative intent and have been free of disease for the time period considered appropriate for the specific cancer.
- No serious concurrent medical illness or active infection should be present which would jeopardize the ability of the patient to receive the chemotherapy outlined in this protocol with reasonable safety.
- Sexually active patients must use an accepted and effective method of contraception while receiving protocol treatment.
- Patients must have a Karnofsky Performance Scale (KPS) score over 50. (Equaling ECOG Performance Scale of 0, 1, or 2).
- Age > 18 years.
- Patient must have failed the Taxotere treatment.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- East Orange, New Jersey
- Baltimore, Maryland
- New Brunswick, New Jersey
- Durham, North Carolina
- Nagoya, Aichi
- Nagoya, Aichi
- Matsuyama, Ehime
- Iizuka, Fukuoka
- Isesaki, Gunma
- Maebashi, Gunma
- Ota, Gunma
- Hakodate, Hokkaido
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Sapporo, Hokkaido
- Mito, Ibaraki
- Sagamihara, Kanagawa
- Yokohama, Kanagawa
- Yokohama, Kanagawa
- Yokosuka, Kanagawa
- Kashihara, Nara
- Kurashiki, Okayama
- Hirakata, Osaka
- Osakasayama, Osaka
- Suita, Osaka
- Kitaadachi-gun, Saitama
- Hamamatsu, Shizuoka
- Utsunomiya, Tochigi
- Bunkyo-ku, Tokyo
- Bunkyo-ku, Tokyo
- Koto-ku, Tokyo
- Nakano-ku, Tokyo
- Shinagawa-ku, Tokyo
- Shinjuku-ku, Tokyo
- Ube, Yamaguchi
- Chiba,
- Chiba,
- Fukuoka,
- Fukuoka,
- Fukuoka,
- Hiroshima,
- Kyoto,
- Nagano,
- Nagano,
- Nagasaki,
- Osaka,
- Osaka,
- Osaka,
- Saga,
- Tokushima,
- Toyama,
- Toronto, Ontario
- Edmonton, Alberta
- Vancouver, British Columbia
- Halifax, Nova Scotia
- Hamilton, Ontario
- London, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Regina, Saskatchewan
- Saskatoon, Saskatchewan
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer | |||
Official Title ICMJE | A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC) | |||
Brief Summary | The purpose of this clinical trial is to find out the effect of epirubicin with estramustine phosphate and celecoxib on PSA and objective response in patients with hormone resistant prostate cancer as well as evaluating the toxicity, quality of life of this combination. Celecoxib is an FDA approved drug to treat arthritis. Epirubicin, alone or with estramustine phosphate has been used in the treatment of hormone resistant prostate cancer. These drugs have demonstrated evidences of tumor blood vessel suppression and combination of these three drugs could possibly arrest further tumor growth or even make the tumor decrease in size. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Prostate Cancer | |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Not Provided | |||
Publications * | Zhong F, Kasimis B, Hwang S, Cogswell J, Chang V, Morales E, Gonzalez M, Boholli I, Ohanian M, Blumenfrucht M: Second Line Treatment of Hormone Resistant Prostate Cancer (HRPC). A Phase II Trial of Epirubicin (E), Estramustine Phosphate (EP) and Celecoxib © Proc Am Soc Clin Oncol, Vol 24 #4754, 2005. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Unknown status | |||
Enrollment ICMJE | 28 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | June 2006 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
NOTE: Patients who have not undergone bilateral orchiectomy must continue LHRH agonist therapy (e.g., depot leuprolide or goserelin) while receiving this protocol therapy.
Exclusion Criteria: | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00218205 | |||
Other Study ID Numbers ICMJE | K-EPIRU-0030-280-US | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Department of Veterans Affairs, New Jersey | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | Department of Veterans Affairs, New Jersey | |||
Verification Date | September 2005 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |